Leukemia

Article	Citations
Quantifying measurable residual disease correctly	3426
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis	3216
CD36 cell surface expression as a surrogate marker to identify ABL/JAK-class kinase fusions in pediatric BCP-ALL	190
ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/− lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study	147
The 5th edition of the WHO classification of haematolymphoid tumors: comments from the Groupe Francophone de Cytogénétique Hématologique (GFCH)	124
Key regulatory roles of PRDM1 in human NK-cell differentiation and activation	124
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial	111
MyCARdiac score: integrating cardiac imaging and biomarkers to predict outcomes in RRMM patients receiving cilta-cel	110
Rheumatoid arthritis and the risk of hematologic malignancies: a nationwide cohort study	108
Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study	98
AI-based hematological malignancy prediction from peripheral blood smears in a large diagnostic laboratory cohort	96
Invasive fungal diseases impact on outcome of childhood ALL – an analysis of the international trial AIEOP-BFM ALL 2009	91
Bidirectional anti-tumor and immunological strategies by targeting GARP–TGF-β axis in adult T-cell leukemia/lymphoma	91
Real life evaluation of AlphaMissense predictions in hematological malignancies	87
Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma	87
Correction: Frequent HLA-DR loss on hematopoietic stem progenitor cells in patients with cyclosporine-dependent aplastic anemia carrying HLA-DR15	87
Diverse mechanisms of leukemogenesis associated with PAX5 germline mutation	83
Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial	82
Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)	82
Mutant IL7R collaborates with MYC to induce T-cell acute lymphoblastic leukemia	81
Characterisation and prognostic impact Of ZRSR2 mutations in myeloid neoplasms	78
An MDM2 degrader for treatment of acute leukemias	76
Clonal medicine targeting DNA damage response eradicates leukemia	76
Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma	70
Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials: a SEER-Medicare analysis	69

Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia	67
Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms	67
MCL1 as a therapeutic vulnerability in Burkitt lymphoma	66
Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core	66
Retraction Note: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide	66
Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation	64
Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia	64
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation	62
Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers	60
Clonal hematopoiesis and its impact on the aging osteo-hematopoietic niche	60
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial	60
Real-time genomic characterization of pediatric acute leukemia using adaptive sampling	56
Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies	56
Essential role of Dhx16-mediated ribosome assembly in maintenance of hematopoietic stem cells	55
DDX41 coordinates RNA splicing and transcriptional elongation to prevent DNA replication stress in hematopoietic cells	53
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries	52
Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase	52
Cohesin mutations in acute myeloid leukemia	51
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma	51
STING is crucial for the survival of RUNX1::RUNX1T1 leukemia cells	50
Combining lenalidomide with erythropoiesis stimulating agents: a party of one	50
Nucleic acid therapeutics as differentiation agents for myeloid leukemias	50
Response to Pfirrmann et al.’s comment on How should we interpret conclusions of TKI-stopping studies	49
Donor selection in T-cell-replete haploidentical donor peripheral blood stem cell transplantation	49
Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment – an intraindividual analysis by the German Study Group for MPN (GSG-MPN)	49
Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia	49
Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia	49
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression	48
Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models	48
Allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with t(16;21)(p11;q22)/FUS::ERG	47
PHF6 suppresses self-renewal of leukemic stem cells in AML	47
Does everyone with newly-diagnosed, untreated acute myeloid leukaemia need remission-induction chemotherapy before advancing to a transplant?	46
CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL	45
Oncogenic dependency on SWI/SNF chromatin remodeling factors in T-cell acute lymphoblastic leukemia	45
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia	44
Transient regulation of RNA methylation in human hematopoietic stem cells promotes their homing and engraftment	44
Hemolytic versus malproductive anemia in large granular lymphocytic leukemia	44
DNA demethylating agents for chemoprevention of oncovirus-associated leukemogenesis	43
Requirement for TP73 and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemia	42
Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials	42
Znf687 recruits Brd4-Smrt complex to regulate gfi1aa during neutrophil development	42
Correction: Mitochondrial regulation of GPX4 inhibition–mediated ferroptosis in acute myeloid leukemia	42
Correction to: Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors	42
Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia	41
METTL3 mediates chemoresistance by enhancing AML homing and engraftment via ITGA4	41
Ppm1d truncating mutations promote the development of genotoxic stress-induced AML	40
A bioinformatics perspective on molecular classification of diffuse large B-cell lymphoma	40
Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia	39
Measurable residual disease (MRD)-testing in haematological and solid cancers	39
Impaired binding affinity of YTHDC1 with METTL3/METTL14 results in R-loop accumulation in myelodysplastic neoplasms with DDX41 mutation	39

miR-196b-Oct1/2 axis regulates DNMT3A-mutant AML pathogenesis	37
Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL	37
CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study	37
Central nervous system involvement in childhood acute lymphoblastic leukemia: challenges and solutions	37
RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort	36
PD-1 expression contributes to functional impairment of NK cells in patients with B-CLL	36
Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study	35
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis	35
Progressive T cell defects correlate with disease outcome in high-count monoclonal B-cell lymphocytosis	35
How should we interpret conclusions of TKI-stopping studies	34
Whole-genome sequencing of myeloproliferative neoplasms revealed dynamic clonal changes in the fibrotic or leukemic transformation and novel FOXP1 mutations in the fibrotic transformation	34
Correction: Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks	34
A primary hierarchically organized patient-derived model enables in depth interrogation of stemness driven by the coding and non-coding genome	34
The exon-junction complex helicase eIF4A3 holds therapeutic potential in acute myeloid leukemia	34
Establishment and characterization of a CCND1-rearranged non-mantle cell lymphoma cell line and patient-derived xenograft model	34
TP53 and CDKN2A alterations define a poor prognostic subgroup in patients with nodal T follicular helper cell lymphoma	34
5-Azacytidine and decitabine induce C > G transversions in both murine and human cells	34
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients	34
Chromosome 9p trisomy increases stem cells clonogenic potential and fosters T-cell exhaustion in JAK2-mutant myeloproliferative neoplasms	34
Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia—a Grand Ouest Against Leukemia (GOAL) study	33
Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm	33
CLL cell-derived exosomes alter the immune and hematopoietic systems	33
A Perturb-seq map of a differentiation hub reveals synergistic vulnerabilities in KMT2A-rearranged acute myeloid leukemia	33
Germline PTPN13 mutations in patients with bone marrow failure and acute lymphoblastic leukemia	33
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib	32
Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms	32
Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants	32
Base edited “universal” donor CAR T-cell strategies for acute myeloid leukaemia	32
Targeting proteostasis in multiple myeloma through inhibition of LTK	31
Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells	31
New criteria for estimating numbers of CD34-positive cells in a graft needed for posttransplant bone marrow recovery	31
BRAFV600E promotes DC3/monocyte differentiation in human gene-engineered HSPCs and causes multisystem histiocytosis	31
A velocity-informed framework for resolving functional stratification in rare human stem cells	31
Isatuximab induces antitumor activity in blastic plasmacytoid dendritic cell neoplasm through cellular cytotoxicity	31
Mitochondrial regulation of GPX4 inhibition–mediated ferroptosis in acute myeloid leukemia	30
Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study	30
Improved CAR-T cell activity associated with increased mitochondrial function primed by galactose	30
Emerging T-cell lymphomas after CAR T-cell therapy	30
Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European Conference on Infections in Leukaemia (ECIL-	30
The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms	30
Functions of the native NPM1 protein and its leukemic mutant	30
The role of ASXL1, SRSF2, and EZH2 mutations in chromatin dysregulation of myelodysplastic neoplasia and acute myeloid leukemia	30
KDM6B protects T-ALL cells from NOTCH1-induced oncogenic stress	29
Cre recombinase promotes leukemogenesis in the presence of both homozygous and heterozygous FLT3-ITD	29
What is radiation-induced acute myeloid leukaemia/can it be accurately identified?	29
Patterns of relapse in patients with multiple myeloma receiving chimeric antigen receptor T cell therapy: a multi-center analysis	29
Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma	29
A novel gene fusion RUNX1/ZNF423 promotes leukemic relapse of NUP98-rearranged AML	29
Correction to: Organ dysfunction, thrombotic events, and malignancies in patients with idiopathic multicentric Castleman disease: a population-level US health claims analysis	28
Relationship among three common hematological premalignant conditions	28
Correction: Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML	28
Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease: a population-level US health claims analysis	28
Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia	28
Correction: Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment	28
Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1–45 years: a Danish cohort study	28
The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasms	27
Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632)	27
A pro B cell population forms the apex of the leukemic hierarchy in Hoxa9/Meis1-dependent AML	27
Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after the BTK inhibitor era	27
Pre-diagnosis dietary patterns and risk of multiple myeloma in the NIH-AARP diet and health study	27
Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study	27
EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma	27
Characterization of immune exhaustion and suppression in the tumor microenvironment of splenic marginal zone lymphoma	27
Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies	27
Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML	27
NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia	27
AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics	27
How fast does leukemia progress?	27
Single-cell RNA sequencing of a new transgenic t(8;21) preleukemia mouse model reveals regulatory networks promoting leukemic transformation	27
Sulforaphane promotes natural killer cell-mediated anti-tumor immune responses partially via cGAS-STING pathway in classical Hodgkin lymphoma	27
S1P-S1PR3-RAS promotes the progression of S1PR3hi TAL1+ T-cell acute lymphoblastic leukemia that can be effectively inhibited by an S1PR3 antagonist	26
Refining histopathological growth pattern-based risk group discrimination in nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group	26
Immunogenetics in hematopathology and hematology: why a common language is important	26
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer	26
T-cell diversity and exclusion of blood-derived T-cells in the tumor microenvironment of classical Hodgkin Lymphoma	26
Leukemogenesis occurs in a microenvironment enriched by extracellular microvesicles/exosomes: recent discoveries and questions to be answered	26
Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction	26
Impact of socioeconomic disparities on outcomes in adults undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia	26
Harnessing upregulated E-selectin while enhancing SDF-1α sensing redirects infused NK cells to the AML-perturbed bone marrow	26
KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia	26

High glutamate levels in the bone marrow of multiple myeloma patients promote osteoclast formation: a novel target for osteolytic bone disease	26
Correction: Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway	25
Inhibition of the m6A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia	25
Are real world data real world data?	25
Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia	25
Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia	25
Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children’s Oncology Group study	25
Impact of emerging ACA on survival in chronic myeloid leukemia (CML)	25
A three-dimensional ex vivo model recapitulates in vivo features and drug resistance phenotypes in childhood acute lymphoblastic leukemia	25
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial	25
miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease	25
Apoliprotein E-mediated ferroptosis controls cellular proliferation in chronic lymphocytic leukemia	24
A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses	24
Profound sympathetic neuropathy in the bone marrow of patients with acute myeloid leukemia	24
Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period	24
The histone demethylase KDM5C functions as a tumor suppressor in AML by repression of bivalently marked immature genes	24
Targeting ZDHHC21/FASN axis for the treatment of diffuse large B-cell lymphoma	24
Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma	24
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study	24
Performance of molecular scoring systems in hypomethylating agent-treated myelodysplastic neoplasms	24
LIN28B promotes differentiation of fully transformed AML cells but is dispensable for fetal leukemia suppression	23
Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment	23
ADH5/ALDH2 dehydrogenases and DNA polymerase theta protect normal and malignant hematopoietic cells from formaldehyde challenge: therapeutic implications	23
Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia	23
Suppression of Rho-associated kinase 1 (ROCK1) promotes human hematopoietic stem cell expansion by attenuating mitochondrial fission	23
Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival	23
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY	23
Sequential BCR::ABL1 evaluation during dose de-escalation in peripheral blood is more predictive of TFR success than single assessment at dose de-escalation in either peripheral blood or bone marrow	23
Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms	23
Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach	23
A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia	22
Targeting UHRF1 induces regression of aggressive mantle cell lymphoma	22
NPM1-fusion proteins promote myeloid leukemogenesis through XPO1-dependent HOX activation	22
Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements	22
SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice	22
Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations	22
Cerebrospinal fluid proteomics exerts predictive potential for immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR-T cell therapy	22
Challenges determining the best target duration of deep molecular response after which to attempt achieving therapy-free remission in chronic myeloid leukaemia	22
Co-variates associated with outcomes of tyrosine kinase-inhibitor therapy in persons with chronic myeloid leukaemia initially presenting in accelerated phase	21
Skin lesions, arthritis, chondritis, and cytopenias	21
Measurable residual disease in chronic lymphocytic leukemia. Where do we stand?	21
Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia	21
Survival with chronic myeloid leukaemia after failing milestones	21
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms	21
Glucose uptake capacity of leukaemia cells in vitro correlates with response to induction therapy in acute myeloid leukaemia	20
Correspondence to “A novel lncRNA SNHG29 regulates EP300-related histone acetylation modification and inhibits FLT3-ITD AML development”	20
Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working p	20
GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma	20
Long read nanopore DNA sequencing with adaptive sampling to identify tyrosine kinase fusion genes	20
Intensive post-remission therapy does not decrease relapse after allotransplants for acute myeloid leukaemia in 1st remission and should not be given	20
Molecular mechanisms underlying transformation of large granular lymphocytic leukemia to high-grade T-cell lymphoma	20
Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX)	20
Acute myeloid leukemia: does sex matter?	19
What do atomic bomb survivors teach us about therapy-free remission in people with chronic myeloid leukaemia?	19
Updates of the ERIC recommendations on how to report the results from immunoglobulin heavy variable gene analysis in chronic lymphocytic leukemia	19
PML::RARα+ myeloid cells display metabolic alterations that can be targeted to treat resistant/relapse acute promyelocytic leukemias	19
High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia	19
High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL	19
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma	19
Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition	19
Clinical phenotypes, molecular analysis, and outcomes of patients with Rosai-Dorfman disease	19
Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young adults compared to children, adults, and BCR::ABL1-positive acute lymphoblastic leukemia	19
RAG1/2 expression in IGH-switched follicular lymphoma associated with transformation to high-grade B-cell lymphoma	19
Enhancing tyrosine kinase inhibitor sensitivity by restoring IKAROS activity on GLUT1 expression and glycolysis in Philadelphia chromosome-positive acute lymphoblastic leukemia	19
P4HA2 hydroxylates SUFU to regulate the paracrine Hedgehog signaling and promote B-cell lymphoma progression	19
Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia	19
A genome-wide association study identifies an African-specific locus on chromosome 21q22.12 associated with Burkitt lymphoma risk and survival	19
Overt and covert genetic causes of pediatric acute lymphoblastic leukemia	19
Prognostic impact of RUNX1 mutations and deletions in pediatric acute myeloid leukemia: results from the French ELAM02 study group	19
Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations	19
Inability to phosphorylate Y88 of p27Kip1 enforces reduced p27 protein levels and accelerates leukemia progression	18
CD40/PI3K/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival	18
Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance	18
Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells	18
Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma	18
PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia	18
OGG1 activation improves T cell resilience to oxidative stress after allo-SCT and T cell engager exposure	18
Characterization of leukemia progression in the Cbfb-MYH11 knockin mice by single cell RNA sequencing	18
A DNA methylation database of human and mouse hematological malignancy cell lines	18
Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia	18
Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemia	18
Improved survival with younger HLA-matched unrelated donors versus older matched sibling donor HCT with PTCy-prophylaxis	18
The protein deacetylase HDAC10 controls DNA replication in malignant lymphoid cells	18
Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes	18
Analysis of autophagy in DLBCL reveals subtype-specific differences and the preferential targeting of ULK1 inhibition in GCB-DLBCL provides a rationale as a new therapeutic approach	18
SF3B1-mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms	18
Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation	18
Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis	18
Correction: Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia	18
Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis	18
Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis	18
Germline CHEK2 mutations in patients with myeloid neoplasms	18
Molecular profiling and risk stratification in solitary bone plasmacytoma	17
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community	17
How well do different chatbots respond to multiple myeloma treatment guidelines?	17